These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17722509)

  • 21. Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.
    Thervet E
    Int J Nanomedicine; 2006; 1(3):269-81. PubMed ID: 17717968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
    Bechstein WO; Paczek L; Wramner L; Squifflet JP; Zygmunt AJ;
    Transplant Proc; 2013; 45(6):2133-40. PubMed ID: 23953523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Hricik DE; Anton HA; Knauss TC; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2002 Jul; 74(2):189-93. PubMed ID: 12151730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus: a new agent for prevention of renal allograft rejection.
    Vasquez EM
    Am J Health Syst Pharm; 2000 Mar; 57(5):437-48; quiz 449-51. PubMed ID: 10711524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Goldfarb DA
    J Urol; 2005 Jun; 173(6):2106-7. PubMed ID: 15879857
    [No Abstract]   [Full Text] [Related]  

  • 31. [Sirolimus offers advantages for kidney transplant patients].
    Med Klin (Munich); 2003 Feb; 98(2):VII. PubMed ID: 12638547
    [No Abstract]   [Full Text] [Related]  

  • 32. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
    Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
    Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comment: delayed wound healing with sirolimus after liver transplant.
    Mathis AS
    Ann Pharmacother; 2003 Mar; 37(3):453. PubMed ID: 12639183
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis.
    Ciancio G; Burke GW; Gaynor JJ; Ruiz P; Roth D; Kupin W; Rosen A; Miller J
    Transplantation; 2006 Mar; 81(6):845-52. PubMed ID: 16570006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus: new preparation. No tangible advance in renal transplantation.
    Prescrire Int; 2002 Dec; 11(62):165-6. PubMed ID: 12469693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
    Mystakidou K; Tsilika E; Tsiatas M; Vlahos L
    Int J Nanomedicine; 2007; 2(1):49-54. PubMed ID: 17722512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient.
    Shinke H; Hashi S; Kinoshita R; Taniguchi R; Sugimoto M; Matsubara K; Ogawa E; Sonoda M; Takada N; Yoshizawa A; Ogawa K; Okamoto S; Uemoto S; Masuda S
    Biol Pharm Bull; 2013; 36(7):1221-5. PubMed ID: 23676788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.